WAVE LIFE SCIENCES LTD. Payments for Repurchase of Initial Public Offering
WAVE LIFE SCIENCES LTD. (WVE) reported Payments for Repurchase of Initial Public Offering of $1.07 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfInitialPublicOffering · last filed 2019-03-01
- WAVE LIFE SCIENCES LTD. payments for repurchase of initial public offering for the quarter ending 2016-12-31 was $0.00.
- WAVE LIFE SCIENCES LTD. payments for repurchase of initial public offering for the quarter ending 2016-09-30 was $0.00.
- WAVE LIFE SCIENCES LTD. payments for repurchase of initial public offering for fiscal 2016 was $1.07M.
| Period end | Payments for Repurchase of Initial Public Offering 3 month | Payments for Repurchase of Initial Public Offering 6 month | Payments for Repurchase of Initial Public Offering 9 month | Payments for Repurchase of Initial Public Offering 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $1.07M 10-K · filed 2019-03-01 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $1.07M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $1.07M 10-Q · filed 2017-08-09 | |||
| 2015-09-30 | $1.42M 10-Q · filed 2016-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |